Get the Stockscreener App
10.35
0.49%
0.05
Pre-market:
10.88
0.53
+5.12%
Cullinan Therapeutics Inc Stock (CGEM) Latest News
SG Americas Securities LLC Has $283,000 Stock Holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Equities Analysts Issue Forecasts for CGEM Q1 Earnings - MarketBeat
HC Wainwright Brokers Decrease Earnings Estimates for CGEM - Defense World
HC Wainwright Boosts Cullinan Therapeutics (NASDAQ:CGEM) Price Target to $33.00 - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Shares Gap Up Following Analyst Upgrade - MarketBeat
Q1 Earnings Forecast for CGEM Issued By HC Wainwright - Defense World
Cullinan Therapeutics (NASDAQ:CGEM) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Cullinan reports zipalertinib study met primary endpoint - MSN
Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference - GlobeNewswire
Cullinan Therapeutics Reveals Next-Gen Pipeline Details at Major Biotech Conference - StockTitan
Cullinan Therapeutics (NASDAQ:CGEM) Shares Gap Up After Analyst Upgrade - Defense World
Cullinan/Taiho’s Zipalertinib Stands To Benefit From A Clear Market - Citeline News & Insights
Cullinan Management Achieves Milestone in Cancer Trial - TipRanks
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Bought by JPMorgan Chase & Co. - Defense World
Cullinan Therapeutics Says Zipalertinib Trial Met Primary Endpoint -January 29, 2025 at 04:38 am EST - Marketscreener.com
Cullinan Reveals Update On REZILIENT1 Trial Data For Zipalertinib In Non-Small Cell Lung Cancer - RTTNews
Game-Changing Lung Cancer Drug Shows Promise: New Hope for EGFR Mutation Patients - StockTitan
Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics Announce Primary Endpoint Met in Phase 2b Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy - PR Newswire
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Stock Position Decreased by Assenagon Asset Management S.A. - Defense World
Reviewing Repligen (NASDAQ:RGEN) and Cullinan Therapeutics (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Average Rating of “Buy” from Analysts - Defense World
Cullinan Therapeutics (NASDAQ:CGEM) Hits New 52-Week LowHere's What Happened - MarketBeat
Harbor Capital Advisors Inc. Purchases 9,385 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics (NASDAQ:CGEM) Shares Down 7.3%Should You Sell? - MarketBeat
Cullinan Therapeutics’ CLN-978 And Zipalertinib Look Promising In NSCLC (NASDAQ:CGEM) - Seeking Alpha
Cullinan Therapeutics: Casting A Wide Net With Their Pipeline (NASDAQ:CGEM) - Seeking Alpha
Jennifer Michaelson Sells 4,000 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Stock - MarketBeat
Cullinan Therapeutics' chief scientific officer sells shares worth $50,040 - Investing.com
Cullinan Therapeutics (NASDAQ:CGEM) Stock Price Down 5.4%What's Next? - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Sees Large Growth in Short Interest - Defense World
Cullinan Therapeutics (NASDAQ:CGEM) Shares Gap UpWhat's Next? - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Sees Significant Increase in Short Interest - MarketBeat
Don't Ignore The Insider Selling In Cullinan Therapeutics - Simply Wall St
Financial Comparison: Genfit (NASDAQ:GNFT) vs. Cullinan Therapeutics (NASDAQ:CGEM) - Defense World
Geode Capital Management LLC Acquires 231,935 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat
Geode Capital Management LLC Buys 231,935 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics CEO sells shares worth $99,708 - Investing.com India
Insider Selling: Cullinan Therapeutics, Inc. (NASDAQ:CGEM) CEO Sells 8,400 Shares of Stock - MarketBeat
Cullinan Therapeutics CEO sells shares worth $99,708 By Investing.com - Investing.com South Africa
Cullinan Therapeutics (NASDAQ:CGEM) Shares Down 2.9%Should You Sell? - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Given Average Recommendation of “Buy” by Analysts - Defense World
Barclays PLC Acquires 51,300 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Trading 5.6% Higher – Here’s Why - Defense World
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Acquired by State Street Corp - Defense World
State Street Corp Increases Stake in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Insider Sells $53,547.13 in Stock - MarketBeat
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):